AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, ...

Mer­ck’s head of R&D Dean Li be­lieves he’s out­foxed his com­pe­ti­tion for the next gen­er­a­tion of on­col­o­gy drugs, ...

Vertex, Kindeva and Convatec pledge £1B+ for UK sites in Healey’s first Budget; Teva closes NJ plant; Regeneron extends ...

Eli Lil­ly once again dom­i­nat­ed rev­enue ex­pec­ta­tions, blow­ing past Wall Street’s es­ti­mates by about $2 bil­lion.

AI agents are booking medical appointments & fighting insurance denials. Zocdoc welcomes agents; General Medicine designs ...

Aspen Neuroscience raises ~$141M and Bambusa ~$169M in Nasdaq IPOs, pushing 2026 biotech IPO haul to ~$8B across 29 deals.

Dren Bio raises $350M to advance blood cancer drug dibotatug toward 2027 market launch, backed by Juvia Group and Lightspeed Venture Partners.

For­ma­tion Bio, an AI-fo­cused biotech that ac­quires out­side as­sets, de­vel­ops them and then hands them off, has raised ...

FDA releases CRISPR medicine framework for personalized gene therapies, building on Baby KJ's case. Danaher's Kassim flags ...

HHS on Wednes­day said it will stop en­forc­ing a ban on the com­pound­ing of cer­tain pop­u­lar pep­tides used for well­ness ...

Anthropic buys Mithril Medicine, a one-person stealth biotech backed by Atlas whose founder ran the “Professor Oak” account ...

Plowshare Therapies, led by Kevin Strauss, aims to develop a gene therapy for maple syrup urine disease, targeting ...